New research suggests that patients who stop using new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end conventional diet and exercise programs.
Research printed in a prominent medical journal points out that while overweight individuals can lose substantial amounts of their total mass while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month after stopping.
"People purchasing these drugs should be aware of the potential of fast weight regain when the medication concludes," warns lead investigator Dr. Susan Jebb.
This pace of regain suggests a reversion to original weight within about 18 months.
Comparing Treatments
The analysis, which examined 37 of studies involving thousands of patients, contrasted the outcomes of these new drugs with other pills.
Scientists point out that individuals who shed pounds through lifestyle changes alone usually experience a slower creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Fast Regain
Doctors suggest the way of the jabs explains the accelerated weight return.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls appetite.
"Sustained high doses of GLP-1 levels several times higher than normal could lead to the body to produce less of its own natural hormone, and could reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' means appetite is unsuppressed, making overeating far more likely."
A Chronic Disease?
The NHS suggest the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, considering the high risk of weight regain, the therapy is often life-long.
This view is reinforced by pharmaceutical companies, who say that the findings "emphasize the long-term nature of excess weight," comparing it to managing conditions like high blood pressure.
User Experiences
Users who have discontinued the jabs describe a intense return of hunger.
"It felt as if something flipping and you become ravenous," described one woman.
This difficulty is compounded if users have not established sustainable lifestyle or habit changes during treatment.
Growing Adoption
Figures indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Use is more common among women compared to males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, experts emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone cure and long-term success relies on ongoing lifestyle changes.